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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) has a broad spectrum of disease states ranging from mild steatosis
characterized by an abnormal retention of lipids within liver cells to steatohepatitis (NASH) showing fat accumulation,
inflammation, ballooning and degradation of hepatocytes, and fibrosis. Ultimately, steatohepatitis can result in liver cirrhosis
and hepatocellular carcinoma.
Methodology and Results: In this study we have analyzed three different mouse strains, A/J, C57BL/6J, and PWD/PhJ, that
show different degrees of steatohepatitis when administered a 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) containing
diet. RNA-Seq gene expression analysis, protein analysis and metabolic profiling were applied to identify differentially
expressed genes/proteins and perturbed metabolite levels of mouse liver samples upon DDC-treatment. Pathway analysis
revealed alteration of arachidonic acid (AA) and S-adenosylmethionine (SAMe) metabolism upon other pathways. To
understand metabolic changes of arachidonic acid metabolism in the light of disease expression profiles a kinetic model of
this pathway was developed and optimized according to metabolite levels. Subsequently, the model was used to study in
silico effects of potential drug targets for steatohepatitis.
Conclusions: We identified AA/eicosanoid metabolism as highly perturbed in DDC-induced mice using a combination of an
experimental and in silico approach. Our analysis of the AA/eicosanoid metabolic pathway suggests that 5-
hydroxyeicosatetraenoic acid (5-HETE), 15-hydroxyeicosatetraenoic acid (15-HETE) and prostaglandin D2 (PGD2) are
perturbed in DDC mice. We further demonstrate that a dynamic model can be used for qualitative prediction of metabolic
changes based on transcriptomics data in a disease-related context. Furthermore, SAMe metabolism was identified as being
perturbed due to DDC treatment. Several genes as well as some metabolites of this module show differences between A/J
and C57BL/6J on the one hand and PWD/PhJ on the other.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is a major cause of
chronic liver damage in western countries and dependent on
genetic and environmental factors. NAFLD can be considered as
the hepatic manifestation of the metabolic syndrome and is linked
to visceral obesity and has a higher prevalence among people with
hyperlipidemia, hypertension, hyperglycemia and insulin resis-
tance [1,2]. Advanced stages of NAFLD, such as steatohepatitis,
ultimately result in fibrosis and cirrhosis and can finally lead to
liver failure or hepatocellular carcinoma (HCC) [3]. The
importance of nonalcoholic steatohepatitis (NASH) in public
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health in the western world is demonstrated by the massive
increase of obesity and type 2 diabetes mellitus, which are key
components of the metabolic syndrome [4].
The molecular basis of complex diseases, such as NASH, is
poorly understood and its analysis requires a detailed understand-
ing of the underlying metabolic and regulatory processes on the
molecular level. Steatohepatitis is characterized by alterations in
the liver, such as steatosis, ballooning of hepatocytes, apoptosis,
protein aggregates in hepatocytes (Mallory-Denk bodies), pericel-
lular fibrosis, and predominantly polymorphonuclear granulocytic
inflammation [3]. Certain features of steatohepatitis can be
reproduced to a variable extent in different mouse models by
various treatments like chronic intoxication with DDC (5-
diethoxycarbonyl-1,4-dihydrocollidine), methionine- and choline-
deficient diet, alcohol or high fat diet [5,6].
Metabolites can be seen as end points of perturbations occurring
at the gene level, so that changes of gene expression might to some
extent also relate to changes in metabolite concentrations. The
metabolic activity changes can be justified from transcript profiles
based on the fact that mRNA is translated into a protein, e.g.,
working as an enzyme, thus changing metabolic flux of its
catalyzed reaction [7]. Analysis of experimental data from cellular
levels, i.e., transcriptomics, proteomics, fluxomics, and metabo-
lomics show that there is not a high overall correlation between the
abundance of RNA and its encoded protein, and between enzyme
abundance and their respective catalyzed flux [7]. However, for
regulated metabolic pathways the changes of RNA and protein
abundances were in accordance with changes in reaction fluxes
[7]. Hence, models integrating metabolic pathways and gene
expression data may be used for in silico studies to predict changes
in metabolite levels. Several tools exist to perform pathway
analysis of expression and/or metabolic data that provide
reasonable candidate pathways for subsequent modeling [8,9].
Past studies already used combined analysis of gene expression and
metabolite data for the identification of, e.g., a genetic network of
liver metabolism [10], biomarkers of type 2 diabetes [11], and
disease related active pathways [12].
Herein, we studied transcriptomics and metabolomics data of
mice developing NASH-like phenotypic features. We fed three
genetically different mouse strains A/J, C57BL/6J, and PWD/PhJ
(henceforth AJ, B6 and PWD) a DDC-supplemented diet. These
mouse strains belong to two different subspecies and therefore
cover a broad genetic variety. AJ and B6 are classical laboratory
mouse strains mainly of Mus musculus domesticus origin, whereas
PWD is a wild-derived strain mainly of Mus musculus musculus
origin. Liver samples of DDC-treated and untreated mouse strains
were analyzed by RNA sequencing (RNA-Seq) providing com-
prehensive mRNA expression profiles. Furthermore, we quantified
selected metabolites by mass spectrometry and some relevant
proteins by reverse-phase protein array (RPPA). Pathway analysis
of these data identified deregulated pathways such as, nucleotide,
beta-alanine and histidine metabolism. Furthermore, strain-
specific deregulation was found in the metabolism of S-adenosyl-
methionine (SAMe). Moreover, the metabolism of arachidonic
acid was identified to be perturbed due to DDC-treatment
irrespective of the strain. For further analysis and correlation of
transcriptomics, protein and metabolite data, a kinetic model of
the arachidonic acid metabolism was developed and fed with
expression data to understand the metabolic changes. The
arachidonic acid metabolic model was further used in an in silico
study to obtain potential drug targets.
Materials and Methods
Mouse experiments and liver preparation
A/J, C57BL/6J and PWD/PhJ (abbreviated AJ, B6, and PWD)
animals were obtained from Jackson Laboratories (The Jackson
Laboratory, Maine, USA) and bred in the animal facility of the
Medical University of Graz under specific pathogen free
conditions. Eight weeks old male animals of each strain were fed
either a standard (control) diet (Ssniff Spezialdia¨ten GmbH, Soest,
Germany) or the standard diet supplemented with 0.1% DDC (5-
diethoxycarbonyl-1,4-dihydrocollidine, Sigma-Aldrich, Vienna,
Austria) for eight weeks under constant health monitoring.
All animal experiments were conducted according to the
Austrian Animal Welfare Act. All experiments were approved by
the Austrian ministry of science and research after review by the
Austrian animal research committee under animal license number
BMBWK-66.010/0047-BrGT/2005. Austrian law does not re-
quire individual institutional animal care and use committees for
universities as all animal experimentation has to be pre-approved
by the Austrian ministry of science and research.
Up to 4 animals were kept in individually ventilated cages at a
monitored temperature of 20–24uC, with humidity between 40–
70%, a constant 12 hour light and dark cycle and at least 50–60
air changes per hour. Animals were provided with water and
rodent chow ad libitum. Animal health was monitored by daily
visual cage inspection and weekly weight check of all experimental
animals. Animals losing more than one third of body weight or
showing other signs of distress due to DDC feeding were excluded
from analysis and immediately sacrificed. All animals were
sacrificed by cervical dislocation after anaesthesia by isoflurane
inhalation. Liver tissues were harvested and samples of liver tissue
were frozen in methyl-butane cooled by liquid nitrogen and
subsequently stored in liquid nitrogen. RNA was prepared from
frozen liver samples using the RNeasy Mini Kit (Qiagen GmbH,
Hilden, Germany) according to manufacturers instructions.
RNA-Seq experiments and data analysis
We performed transcriptome analysis of healthy and DDC-
treated livers of three mouse strains AJ, B6, and PWD each, and
three biological replicates per strain and condition. In total, 18
paired-end RNA-Seq libraries were prepared from 10 mg of total
RNA using a strand-specific strategy and following the protocol
described in [13]. The following ligation adapters and PCR
primers were used: PE Adapter OligoMix (Cat.#1001782),
PCR Primer PE 1.0 (Cat.#1001783), PCR Primer PE2.0
(Cat.#1001784), IndexPE Adapter Oligo Mix Cat.#1005711),
PCR PrimerInPE 1.0, (Cat.#100571), PCR PrimerInPE 2.0,
(Cat.#1005713). Sequencing was carried out on the GAIIx
platform (Illumina) by running 2651 cycles according to the
manufacturer instructions. Sequencing reads were aligned to the
mm9 assembly of the mouse reference genome using BWA [14].
Gene levels were then quantified in reads per kilobase of exon
model per million mapped reads [15] and using the Ensembl v.53
(Mus musculus) annotation. Identification of differentially ex-
pressed genes (DEGs) was performed with the R-package ‘‘edgeR’’
[16]. For identification of DEGs three biological replicates of each
mouse strain AJ, B6, and PWD for control and DDC-treated states
were used. DEGs were identified in two ways: (i) ‘‘strain-wise’’ and
(ii) ‘‘irrespective of strains’’. For strain-wise identification DEGs
between DDC-treated and control states were computed sepa-
rately for each mouse strain AJ, B6, and PWD, while for the
identification irrespective of strains control and DDC-treated
states were analyzed across all three mouse strains together. Using
edgeR p-values were calculated and adjusted for multiple testing
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using the Benjamini-Hochberg procedure implemented in edgeR.
Principal components analysis (PCA) was performed to investigate
any grouping of strain-wise DEGs.
Metabolomics analysis
Acylcarnitines, Sphingomyelins, Hexoses, Glycerophos-
pholipids (FIA-MS/MS). To determine the concentration of
acylcarnitines, sphingomyelins, hexoses and glycerophospholipids
in liver homogenate the AbsoluteIDQ kit p150 (Biocrates Life
Sciences AG) was prepared as described in the manufacturer’s
protocol. In brief, 10 ml of liver homogenate was added to the
centre of the filter on the upper 96-well kit plate, and the samples
were dried using a nitrogen evaporator (VLM Laboratories).
Subsequently, 20 ml of a 5% solution of phenyl-isothiocyanate was
added for derivatization. After incubation, the filter spots were
dried again using an evaporator. The metabolites were extracted
using 300 ml of a 5 mM ammonium acetate solution in methanol.
The extracts were obtained by centrifugation into the lower 96-
deep well plate followed by a dilution step with 600 ml of kit MS
running solvent. Mass spectrometric analysis was performed on an
API4000 QTrap tandem mass spectrometry instrument (Applied
Biosystems/MDS Analytical Technologies) equipped with an
electro-sprayionization (ESI)-source using the analysis acquisition
method as provided in the AbsoluteIDQ kit. The standard FIA-
MS/MS method was applied for all measurements with two
subsequent 20 ml injections (one for positive and one for negative
mode analysis). Multiple reaction monitoring (MRM) detection
was used for quantification applying the spectra parsing algorithm
integrated into the MetIQ software (Biocrates Life Sciences AG).
Prostanoids, oxidized fattyacids (LC-MS/MS). Prostanoids –
a term summarizing prostaglandins (PG), thromboxanes (TX) and
prostacylines – and oxidised fatty acid metabolites were analyzed by LC-
ESI-MS/MS [17] by online solid phase extraction (SPE)-LC-MS/MS
with an API4000 QTrap tandem mass spectrometry instrument
(Applied Biosystems/MDS Analytical Technologies) in negative
MRM detection mode. In brief, filter spots in a 96 well plate were
spiked with internal standard; 20 ml of sample were added and extracted
with aqueous methanol, the individual extracts then were analysed.
Data of prostanoids and oxidized fatty acids were quantified with
Analyst 1.4.2 software (Applied Biosystems) and finally exported for
statistical analysis.
Protein preparation
Proteins were isolated from fresh-frozen tissue using T-Per
extraction reagent (Pierce Biotechnology, Inc., Rockford, IL, USA)
according to the manufacturer’s recommendations, with the
addition of the following inhibitors: complete mini protease
inhibitor cocktail, staurosporin and PhosStop (Roche, Mannheim,
Germany). For protein extraction from tissue (30–40 mg) the
Qiagen Tissuelyser (Qiagen, Hilden, Germany) was used. Samples
were isolated in 10 ml protein lysis buffer per 10 mg sample.
Protein concentrations were determined using the bicinchoninic
acid assay reagents (Pierce Biotechnology, Inc.). Protein lysates
were stored at 280uC.
Reverse-phase protein array (RPPA) processing and data
analysis
Protein lysates were diluted using protein lysis puffer (2 mg/ml).
After adding Tween 20 (0.05%, v/v) protein lysates were printed
onto nitro-cellulose coated glass slides (Oncyte Nitrocellulose Film
Slides, Grace Bio-Labs, Blend, OR, USA) using the Aushon 2470
solid-pin tool arrayer (Aushon Biosystems, Billerica, MA, USA).
Antibody incubation and antibody-mediated signal amplification
were performed as described [18]. Slides were scanned with the
Odyssey NIR scanner (LI-COR Biosciences, Bad Homburg,
Germany). Image analysis was carried out with GenePix-Pro 6.0
(Axon Instruments, Sunnyvale, USA). Data sets were analyzed
using the RPPAnalyzer package [19]. Quantification results were
normalized to the Fast Green FCF staining of total proteins as well
as to the median antibody binding signal levels [20].
Antibody validation for RPPA
To verify antibody specificities, a pool of protein lysates from
cancer and benign tissues was analyzed by SDS-PAGE followed
by Western Blotting. 25 mg of the protein lysate was used and a
standard near-infrared detection was applied as described in [18].
Antibodies with a predominant single band in the expected size
range were selected for further RPPA analysis. Antibodies were
purchased from Cell Signaling Technology (Danvers, MA, USA).
Model Initialization
An example of mapping RNA-Seq or RPPA data to enzyme
concentration is described below. Assume a mass action kinetic
equation,
v~kcat|E|S
where v is the flux, kcat is the enzymatic turnover number, and E
and S are the enzyme and the substrate concentrations,
respectively. The aforementioned equation is transformed in
equation,
v~vmax|u|S
where vmax is the maximum rate and u is a unitless quantity
representing a ratio. For the initialization of the scaling factor u
with RNA-Seq or RPPA data we use 1 for the control state and the
ratio between treatment and control for the DDC-supplemented
state. The ratio is computed based on the experimental
transcriptomics and proteomics data form mice fed 8 weeks with
a DDC-supplemented diet and their respective controls. The state
after 8 weeks is assumed as a quasi steady state also regarding the
quantified metabolite concentrations.
Modelling and kinetic parameter optimization
The mathematical model of the arachidonic acid (AA)/
eicosanoid pathway was developed in PyBioS [21,22] based on
information from KEGG and a survey of literature [23–26].
Parameter optimization of the mathematical model was performed
with COPASI [27]. COPASI provides a number of different
algorithms for optimization of a predefined objective function. We





x½ e{ x½ s,p
 2s
where x is a given metabolite of a set of metabolites M of our
metabolic model, [x]e and [x]s are concentration values of a
metabolite x from experiments and simulations, respectively, and
p is a set of kinetic parameters. x½ s,p is the steady state
concentration of metabolite x during simulation which depends
on p. minfp is an optimization problem which minimize f over p.
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Results
Liver samples of DDC-treated and untreated mouse strains (AJ,
B6 and PWD) were phenotypically characterized and analyzed by
RNA-Seq providing comprehensive mRNA expression profiles, by
mass spectrometry of selected metabolites, and by RPPA analysis
of relevant proteins.
Phenotypic characterization
Phenotypes of liver samples of all three mouse strains after eight
weeks of a DDC-supplemented diet were characterized by
histological examination and formation of Mallory-Denk bodies
using immunohistochemical analysis of ubiquitin and p62
(Fig. 1a). Steatosis was observed to a medium degree in AJ and
PWD while it was absent in B6. Ballooning of the hepatocytes and
the occurrence of ubiquitin and p62 containing protein aggregates
was most pronounced in AJ. Based on the degree of steatohepatic
features AJ and B6 were categorized as high and low susceptible,
respectively, while PWD is resistant.
Identification of differentially expressed genes using
RNA-Seq data
Using RNA-Seq data differentially expressed genes (DEGs) in
response to DDC treatment were computed (i) ‘‘strain-wise’’ and
(ii) ‘‘irrespective of strains’’ as described in the material and
methods section. The total number of DEGs from strain-specific
analysis was very similar between the strains with 1,645, 1,657 and
1,373 for AJ, B6 and PWD, respectively (Fig. 1b). In total, 516
genes were deregulated in all three strains in response to DDC
feeding, whereas 471 DEGs were found exclusively in AJ (Fig. 1b,
Table S1). We call these 471 genes susceptibility genes since this
strain shows the most pronounced steatohepatitis phenotype. In
addition, to address the DDC treatment effect a principle
component analysis (PCA) was performed based on 2,813 genes
(Table S2), which were differentially expressed in at least one
mouse strain due to DDC treatment (Fig. 1c). While healthy mice
show strain-specific expression profiles in PCA, all mouse profiles
from DDC treatment group together, implying a similar overall
response due to DDC treatment irrespective of the strain (Fig. 1c).
Besides the strain-specific analysis, DEGs were also computed
irrespective of strains. This analysis yields in total 4,215 DEGs in
response to DDC treatment (Table S3).
Analysis of proteomics data
For a screening of changes of the proteome some specific
proteins were also analyzed by reverse phase protein arrays
(RPPA; Table S4). Notably, the protein expression levels of the
liver-type fatty acid-binding protein (Fabp1) are decreased in all
strains after DDC-feeding. This observation is in agreement with
data from human samples showing an underexpression in mild
and progressive stages of NASH but paradoxically an overexpres-
sion in simple steatosis [28]. Furthermore, keratin 8 (Krt8) and
keratin 18 (Krt18) were found to be upregulated after DDC
treatment. Both proteins are major components of the hepatocyte
cytoskeleton. Other proteins that were found to be upregulated are
glutathione S-transferase alpha (Gsta1) and glutathione S-trans-
ferase mu (Gstm1) that are both involved in detoxification
processes and catalyze the conjugation of reduced glutathione to
xenobiotics. Notably, the level of glutathione S-transferase alpha
upregulation in AJ and B6 mice is much higher compared to
PWD. Moreover, the protein expression level of the cytochrome
Cyp2e1 level is found to be down-regulated in PWD, while it is not
changed in B6 and AJ mice. In addition to general protein
amounts, also phosphorylated states of the key signaling proteins
Erk1 (Mapk3), Akt1 and Stat3 were measured reflecting the
activity states of their respective signaling pathways. All of them
were found to be induced due to DDC treatment.
Pathway analysis of metabolic profiles and gene
expression data
Besides gene expression and proteomics data, also 44 metab-
olites were identified and quantified by mass spectrometry.
Differences in metabolite concentrations due to DDC treatment
were judged by t-test (Table S5). A pathway analysis of metabolic
profiles and gene expression data was performed with Consensus-
PathDB to identify steatohepatitis-specific pathways [29]. Pathway
over-representation analysis of the aforementioned 471 suscepti-
bility genes obtained only in AJ identified nucleotide, histidine,
beta-alanine, purine metabolism, apoptosis and steroid hormone
biosynthesis upon the top-ranked deregulated pathways (Table
S6). Within the beta-alanine pathway we found Srm encoding
spermidine synthase (SPDS) as being upregulated in AJ (2.44-fold
in AJ compared to 0.77-fold and 0.75-fold in B6 and PWD,
respectively, Tab. S2) as well as the related metabolites spermidine
(SPD) and spermine (SPM) that form a module of the hepatic S-
adenosylmethionine (SAMe) metabolism (Fig. 1d, [30]). SAMe is
needed for methylation of DNA, RNA and lipids, and synthesis
and catabolism of SAMe is tightly regulated and changes in SAMe
level might lead to fatty liver disease and the development of HCC
[30].
Gene expression and metabolite concentrations of hepatic
SAMe metabolism were found to be affected in the DDC-treated
state (Fig. 1e and 1f). Expression of the genes methionine
adenosyltransferase 1 alpha (Mat1a), spermine synthase (Sms),
DNA methyltransferase 1 (Dnmt1), adenosylhomocysteinase
(Ahcy), betaine-homocysteine methyltransferase (Bhmt), and sper-
midine synthase (Srm) and concentration changes of the related
metabolites spermidine, spermine and putrescine show a different
behavior between AJ, B6 and PWD. Gene expression and
metabolic profiles of hepatic SAMe metabolism imply that PWD
has an opposite response compared to AJ and B6 after feeding a
DDC-supplemented diet which resembles the differences in
steatohepatitis phenotypes of the strains. The enzyme SAMe
decarboxylase (SAMDC) is activated by putrescine and upregula-
tion of spermidine synthase (SPDS) and spermine synthase (SPMS)
might explain the increased concentration of spermidine (SPD)
and spermine (SPM) in AJ. A higher concentration of putrescine in
AJ and B6 lowers the Km of SAMDC activating polyamine
synthesis [30] that may affect the concentration of SAMe. This
might affect methylation of various substrates such as DNA, RNA
and lipids that might be one reason in NASH disease develop-
ment. However, it remains difficult to judge the difference in
degree of steatoheapatitis since the expression data and metabolic
profiles of AJ and B6 show a similar response to the DDC-
supplemented diet.
NAFLD has been defined as a metabolic disease associated with
the insulin-resistance syndrome [1]. A genome-scale metabolic
network of the mouse comprising 3,724 reactions, 2,774 metab-
olites, and 1,415 enzyme coding genes was used as a reference to
identify metabolic pathways of related genes [31]. Irrespective of
strain-specific effects, a group of 288 genes (out of 4,215 DEGs)
coding for metabolic enzymes of the genome-scale metabolic
network were identified as differentially expressed (edgeR p-value
,1e-6 over all three strains) after DDC treatment (Table S7). This
set of 288 genes was subsequently used in a pathway analysis with
ConsensusPathDB to identify affected metabolic pathways due to
DDC treatment (Table S8). Furthermore, a set of 19 differentially
regulated metabolites (t-test p-value ,0.05, Table S5) was used for
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a metabolite-based over-representation analysis with Consensus-
PathDB (Table S9). Both, the pathway analysis of the transcrip-
tomics as well as the metabolic data set, yield the arachidonic acid
pathway upon others as being deregulated after DDC treatment
(p-value 2.6e-4 and 1.3e-4, respectively, Table S8 and S9).
Analysis of metabolites of the arachidonic acid/eicosanoid
pathway yield also significant changes due to DDC treatment of
some metabolites of this pathway. The abundances of four
metabolites of this pathway are significantly altered due to DDC-
treatment: PGD2, 5-HPETE, 15-HETE, and 15-HPETE (p-
value,0.05, Table S4). An increased activity of the arachidonic
acid pathway could also be observed in the metabolic data. Based
on these observations we selected the arachidonic acid metabolism
as a candidate for further in silico analysis.
Model of the arachidonic acid/eicosanoid metabolic
pathway
Arachidonic acid (AA) is a fatty acid usually coming from
dietary animal sources or being synthesized from dietary linoleic
acid. AA is present in cell membranes as a part of phospholipids.
AA is released from phospholipids by phospholipase A2 (PLA2)
and subsequently it acts as a precursor of prostaglandins and their
related compounds, the prostacyclins, thromboxanes and leuko-
trienes. Several physiological effects of prostaglandins are
described in the literature, such as inflammatory response, pain,
fever, blood pressure, blood clotting, and regulation of sleep/wake
cycle [32,33]. Cyclooxygenase-1, also known as prostaglandin H2
synthase 1 (Ptgs1), catalyzes the reaction of arachidonate to
prostaglandin H2 (PGH2), which is the precursor of other
prostaglandins, prostacyclins, and thromboxanes. The enzyme 5-
lipoxygenase (Alox5) produces 5-HPETE, which is a precursor of
leukotrienes. The metabolites PGD2, 5-HPETE, 15-HETE and
15-HPETE have been observed to be significantly (p,0.05)
changed in concentration due to DDC treatment in the liver
samples of all mouse strains (Table S5).
There are only a few kinetic models of the AA metabolism
available in the literature to study anti-inflammatory drugs of
human polymorphonuclear leukocytes [23] and macrophage cells
[24]. Here, an in silico model of the AA metabolism in mouse liver
was developed based on information from KEGG [26] and a
biochemical text book [25] to study the regulation of the perturbed
metabolites using the related transcriptome and protein data. The
structure of the model is depicted in Fig. 2.
The downstream synthesis of prostaglandins and leukotrienes is
initiated by signaling and subsequent release of AA catalyzed by
phospholipase A2 (PLA2). In endothelial cell-pericyte co-cultures
of rat cells it has been shown that PLA2 is induced through the
activation of the MAPK/ERK cascade [34]. PLA2 is involved in
inflammation driven liver fibrosis as a key feature of progressive
NASH and macrophage PLA2 deficiency prevented activation of
hepatic stellate cells and infiltration of F4/80-positive macrophag-
es [35]. 15-lipoxygenase (ALOX15) is an important regulator of
inflammation and apoptosis and its expression is regulated by a
cytosolic signaling complex with protein kinase C delta (PKCD)
and phosphorylated STAT3 [36]. Thus, to describe the activity of
PLA2 and PKCD, respectively, RPPA data of phosphorylated
ERK and STAT3 was used subsequently for the modeling (Table
S4).
The eicosanoid pathway is regulated by several feedback
mechanisms (see Fig. 2). The release of AA is controlled by an
inhibitory link between AA and phospholipase A2 (PLA2, R1 in
Fig. 2, [37]). PLA2 is activated by phosphorylated ERK (p-ERK).
Presence of both PLA2 and p-ERK is necessary to drive the
metabolic conversion of phosphatidylcholine (PC) into AA (see R1
in Fig.2). To reflect the inhibition of PLA2 by AA an inhibitory
feedback link is added to R1. The activity of 5-lipoxygenase
(ALOX5) catalyzing the production of 5-HPETE and leukotriene
A4 (LTA4) is controlled by product inhibition and by the ALOX5-
activating protein ALOX5AP (R2, R4, [38,39]). To convert AA
into 15-HPETE the presence of both ALOX15 and a complex
with PKCD and STAT3 are necessary. The production of 15-
HPETE is also controlled by an inhibitory link between 15-
HPETE and ALOX15 which is added to R6 (Fig. 2, [23]).
Synthesis of 15-HPETE and PGH2 are controlled by feedback
inhibition and glutathione peroxide and PTGS1, respectively (R7
and R9, [23,40].
We hypothesize that changes of metabolite concentrations of
the AA pathway can be explained by changes in mRNA
expression. To address this hypothesis, changes in Vmax values of
enzymatic reactions were approximated by fold changes of RNA-
Seq expression of the respective enzymes due to DDC treatment.
The fold change of PLA2 was approximated by Pla2g4a which
was expressed at a low level (,1 RPKM, [41]) but not
differentially (Table S10). Therefore, we hypothesize that PLA2
is at least present to trigger AA release upon its activity state, but it
is not differentially expressed due to DDC treatment. Similarly,
ALOX5 and ALOX15 were approximated by Alox5 (p-
value = 0.13) and Alox15 (p-value = 0.62), respectively, which
were expressed at low level (,1 RPKM) and we hypothesize that
the expression of these genes were not affected due to DDC-
treatment. PTGDS is approximated by Ptgds expression, but it
was not significantly changed due to DDC treatment (p-
value = 0.64). If there are several isoenzymes that can catalyse
the same reaction the most significantly differentially expressed
gene was chosen. For instance, GPX can be approximated by
Gpx1, Gpx2, Gpx3, Gpx6 and Gpx7. Since Gpx3 was significantly
affected (p = 2.66e-41) and highly expressed it was used to initialize
the GPX expression in the model. Fold changes of the enzymes
PTGS1, ALOX5AP and PKCD were approximated by expression
Figure 1. Analysis of phenotypic and omics data. a) Qualitative scoring of histological phenotypes of the mouse liver samples. Score -1, absent;
score 0, minimal; score 1, mild; score 2, moderate; score 3, severe changes compared to healthy liver tissue. Immunohistochemistry, IHC. b) Venn
diagram of differentially expressed genes due to DDC treatment in AJ, B6, and PWD mice. c) Principle component analysis (PCA) of 2813 genes that
were found differentially expressed for at least one mouse strain due to DDC-treatment. * and + indicate control and DDC mice, respectively; red,
green and blue represent AJ, B6, and PWD mice, respectively. Principle component 1 (PC1) explains 43% and PC2 29% of the data. d) S-
adenosylmethionine (SAMe) metabolism. Methionine (Met) is converted to SAMe by the enzyme methionine adenosyltransferase (MAT1). SAMe is
converted into S-adenosylhomocysteine (SAH) by DNA-methyltransferase (DMTs) and SAH hydrolase (AHCY) with homocysteine (Hcy) as an
intermediate. SAH is substrate for Met formation by betaine-homocysteine methyltransferase (BHMT). SAMe can also be converted into spermine
(SPM) via decarboxylated SAMe (dcSAMe) and spermidine (SPD) catalyzed by SAMe decarboxylase (SAMDC), SPD synthase (SPDS), and SPM synthase
(SPMS). This pathways is regulated by putrescine, which activates SAMDC. e) Arithmetic mean values of RPKM values of aforementioned genes for
liver samples of control and DDC-treated mice. Error-bars indicate standard deviations. The bar chart shows log2-ratios of RPKM values of DDC-
treated vs control. The genesMat1a, Srm, Sms, Dnmt1, Ahcy, and Bhmt encode the enzymes MAT, SPDS, SPMS, DMTs, AHCY and BHMT, respectively. f)
Bar chart of median concentrations of the metabolites prostaglandin D2 (PGD2), leukotriene D4 (LTD4), methionine (Met), spermidine, spermine, and
putrescine. Error-bars indicate median absolute deviations. * indicates samples without a replicate.
doi:10.1371/journal.pone.0111006.g001
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values of Ptgs1, Alox5ap and Prkcd, respectively. Within our
experiments the protein amount of phosphorylated ERK (p-ERK)
and phosphorylated STAT3 (p-STAT3) were measured for both
control and DDC-treated mice using the reverse phase protein
array (RPPA) technology. For this we made use of respective
proteomics data and initialized the model components p-ERK and
p-STAT3 based on RPPA data. Since p-ERK and p-STAT3 were
upregulated due to DDC treatment (Table S4; fold changes of p-
ERK and p-STAT3 in AJ, B6, and PWD are 1.90, 2.09, 1.98, and
1.41, 1.42, 2.03, respectively) the effect of p-ERK on PLA2 is
modeled by the RNA-Seq expression value of Pla2g4a for the
DDC-treatment simulation and the p-ERK ratio. Similarly, the
effect of the complex formation of PKCD and p-STAT3 on the
ALOX15 activity was described by the RNA-Seq expression value
of ALOX15 of the DDC-treatment state and the fold change of p-
STAT3 and PKCD, respectively. Phosphatidylcholine (PC) was
modeled as a fixed component and as its initial concentration the
measured concentration of phosphatidylcholine C33:2 was used
(Table 1). The experimentally identified fold changes of all
enzymes are summarized in Table 1 and were used to approx-
imate the kinetic parameters of the respective reactions. The
kinetic parameters of the model were optimized by an objective
function integrating the experimental data (see parameter
optimization in section Material and Methods). Using data of
Figure 2. Model of arachidonic acid/eicosanoid metabolism. The model has three branches. Through the first branch arachidonic acid (AA)
forms leukotriene A4. In the second branch 15-HPETE and 15-HETE are derived from AA, while in the third branch AA forms prostaglandin D2. See the
results section for a detailed description of the model inhibitory links. Phosphatidylcholine, PC; arachidonic acid, AA; phospholipase A2, PLA2;
phosphorylated ERK, P-ERK; cyclooxygenase-1, also known as prostaglandin G/H synthase 1, PTGS1; protein kinase C delta, PKCD; signal transducer
and activator of transcription 3, STAT3; arachidonate 15-lipoxygenase, ALOX15; arachidonate 5-lipoxygenase, ALOX5; arachidonate 5-lipoxygenase-
activating protein, ALOX5AP; prostaglandin H2, PGH2; prostaglandin D2, PGD2; prostaglandin D2 synthase, PTGDS; 15-hydroxyeicosatetraenoic acid,
15-HETE; 5- and 15-hydroperoxyeicosatetraenoic acid, 5- and 15-HPETE; leukotriene A4, LTA4; glutathione peroxidase, GPX.
doi:10.1371/journal.pone.0111006.g002
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DDC treatment vs. control we built a quantitative model to
explain changes of metabolites of the eicosanoid pathway due to
treatment by DDC that mimics the NASH phenotype.
Model Optimization
Model parameters were optimized using experimentally deter-
mined metabolite concentrations of the model components.
Metabolite concentrations were measured after 8 weeks of DDC
treatment and interpreted as steady state concentrations for the
model. The metabolites PGD2, 5-HPETE, 15-HPETE and 15-
HETE have been found as being affected due to DDC treatment.
These metabolites as well as upstream AA were used for model
optimization. Therefore, the model was simulated into its steady
state and the euclidean distance between simulated steady state
concentrations and experimental metabolite data of the afore-
mentioned metabolites were used in an objective function to
optimize the kinetic parameters using COPASI. Parameter
optimization was done using the metabolic concentrations of B6
control and B6 DDC mice. Kinetic parameters, i.e., the maximum
reaction rates (Vmax), Michaelis-Menten constants (Km) and
inhibition constants (Ki) were optimized based on experimental
data. The following five metabolites of the AA model were used to
formulate an objective function: AA, 5-HPETE, and 15-hydro-
peroxyeicosatetraenoic acid (15-HPETE), 15-Hydroxyeicosate-
traenoic (15-HETE), and prostaglandin D2 (PGD2). Let afore-




























where, p is a set of kinetic parameters of the AA model. ec and sc
represent experimental and simulated steady concentration in
control condition, while ed and sd represent experimental and
simulated steady concentration in the DDC-treated condition.
The objective function f was minimized to obtain optimal kinetic
parameters of the AA model using the genetic algorithm of
COPASI with a population size of 50 and a generation size of 500.
The identified kinetic parameters are listed in Table 2. The model
is available in SBML format (suppl. File S1).
Results of the fitted model for the metabolites AA, PGD2, 5-
HPETE, 15-HPETE, and 15-HETE using the trained B6 model
were compared with the experimental results (Fig. 3; C57Bl6_sim
vs. C57Bl6_exp). Except of AA all of the aforementioned
metabolites were up-regulated (.1.5 fold) in both, experimental
and simulated data, due to DDC in B6 mice (Fig. 3c). AA was not
found altered in the experimental data set, but was slightly up-
regulated in the simulation (1.35-fold).
For validation of the model we predicted DDC-induced
metabolite changes for AJ and PWD using the trained model.
Simulation results predict an up-regulation (.1.5-fold) of 5-
HPETE, 15-HPETE and 15-HETE in both strains, which was in
line with the experimental data. The concentration of PGD2 was
found increased (.1.5-fold) between experimental and simulated
data for PWD (Fig. 3c). In AJ our modeling approach predicts a 2-
fold increase of PGD2 concentration in response to the DDC-
treatment, but the experimental data showed no changes (0.9 fold).
This disagreement can be strain-specific because one can expect
changes in the concentration of PGD2 due to an up-regulated
gene expression of Ptgs1 which is located upstream in the
metabolic pathway. AA was up-regulated (.= 1.5-fold) in DDC-
PWD mice, which is concordant with the experimental data, while
for AJ AA is not found as being changed (0.9 fold) in the
experimental data, whereas a minor up-regulation (1.2-fold) was
predicted by the simulation (Fig. 3c).
Key regulatory enzymes of the DDC mouse model
To identify key regulatory enzymes of the AA/eicosanoid
pathway in DDC treated mice, a kind of sensitivity analysis of the
trained model was performed. Starting with DDC-treated mice of
the AJ strain, each enzyme or enzyme combinations were reverted
to its/their activity in normal, untreated condition. This analysis
was performed for ALOX5AP, GPX, PKCD, PTGS1, pERK,
and pSTAT3 whose activity was found to be perturbed due to
DDC-treatment. A reference state was defined where the activity
of all enzymes is equal to the normal condition. Results of this
analysis are depicted in Fig. 4a. Reverting a single enzyme or
combinations of two enzymes were not sufficient to bring the
DDC-treated state back to normal because it affects only some
branches of the model, as for example a change in the activity of
ALOX5 has an effect on the regulation of the downstream
metabolites 5-HPETE and LTA4 (cf. Fig. 2). We found that the
Table 1. Initial values of the arachidonic acid/eicosanoid metabolic model.
Symbol AJ, control AJ, DDC B6, control B6, DDC PWD, control PWD, DDC
PTGS1 1.00 2.13 1.00 1.41 1.00 2.09
ALOX5 1.00 1.00 1.00 1.00 1.00 1.00
PTGDS 1.00 1.00 1.00 1.00 1.00 1.00
STAT3 1.00 1.41 1.00 1.42 1.00 2.03
PKCD 1.00 4.30 1.00 4.48 1.00 3.85
GPX 1.00 6.51 1.00 11.70 1.00 19.42
PLA2 1.00 1.90 1.00 2.09 1.00 1.98
ALOX5AP 1.00 4.81 1.00 6.30 1.00 14.23
ALOX15 1.00 1.00 1.00 1.00 1.00 1.00
PC* 269.00 206.00 249.00 209.00 266.00 255.00
The enzyme concentrations of the control state were always initialized with 1.0 nM. The DDC initial value always reflects the fold change between the DDC-treated
and the control expression value. The absolute concentration of phosphatidylcholine C33:2 (PC*) comes from MS-analysis and is measured in mM for control and DDC-
treatment conditions of AJ, B6, and PWD mice.
doi:10.1371/journal.pone.0111006.t001
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combinations of the enzymes ALOX5AP, PKCD and PTGS1
with either pERK or pSTAT3 can bring the DDC-treated
metabolic state back to normal, with the exception of 15-HETE
and AA. Only the combination ALOX5AP, PERK, PKCD,
STAT3, and PTGS1 or the combination of all six enzymes was
able to bring back the DDC-treated state to normal.
Simulating drug effects in the DDC mouse model
To study potential drug targets for steatosis or inflammation in
silico drug tests were performed. For instance, cyclooxygenase-2
(PTGS2/COX-2) is a frequent target of anti-inflammatory drugs
[42]. In the computer simulation, the activity of each enzyme of
the AJ DDC model was inhibited by 3-, 6- and 9-fold, respectively.
The calculated effects of those enzyme inhibitions on the
regulation of metabolites are shown in Fig. 4b. The inhibition of
PTGS1 and ALOX5AP leads to a down-regulation of the
respective downstream components (either PGH2 and PGD2 or
5-HPETE and LTA4). ALOX15 is activated by PKCD and
pSTAT3, and the inhibition of PKCD or pSTAT3 leads to a
down-regulation of the downstream components 15-HPETE and
15-HETE. It can be expected that the inhibition of glutathione
peroxidase (GPX) leads to a down-regulation of the downstream
component 15-HETE, but the model predicts an up-regulation of
15-HPETE and no change in 15-HETE. This is due to the
complex regulation of ALOX15, i.e., an activation of the complex
PKCD and pSTAT3 and an inhibition of GPX by 15-HETE.
Discussion
Using a DDC-based mouse model of steatohepatitis we
analyzed three different mouse strains AJ, B6, and PWD covering
a broad range of genetic variations. AJ, B6, and PWD mice
respond with different degrees of steatohepatitis ranging from
high, low to resistant, respectively. Based on gene expression and
metabolic data we identified differences in hepatic SAMe
metabolism in respect to the different steatohepatitis phenotypes
across the individual mouse strains. SAMe metabolism might
explain susceptibility of AJ mice. SAMe is a key methyl-group
donor for phosphatidylcholine synthesis that is required, e.g., for
the export of very-low-density lipoproteins (VLDL) and triglycer-
ides from the liver [43]. Furthermore, VLDL synthesis has been
found to be impaired by MAT1A-knockout that could be
recovered by SAMe administration in MAT1A deficient mice
[43]. SAMe and methionine metabolism was found to be
perturbed in NASH patients [44] and it may play an important
role in development of NAFLD, such as NASH [30]. A study
suggests depletion of hepatic anti-oxidants (e.g. reduced glutathi-
one and SAMe) promotes oxidative stress and may induce cellular
alterations typical for steatohepatitis [6].
We identified AA metabolism as being the most affected one
upon all of the three mouse strains and we propose a dynamic
model of AA metabolism of NASH-like phenotypes in mouse
induced by DDC. The fitted model provides good predictions
between the experimental and simulated metabolic data using the
respective gene expression data.
To determine regulatory roles of important enzymes in the
upregulation of metabolic levels of the AA/eicosanoid pathway
due to DDC-treatment, a sensitivity analysis was performed by
reverting to the activity of the enzymes to normal, untreated
conditions. The simulated combination of the enzymes
ALOX5AP, PERK, PKCD, STAT3, and PTGS1 is able to
revert the DDC-treated metabolic state to normal. This multi-
targets inhibition might likely become a future approach in respect
to individualized medicine as it has already been suggested for
cancer [45].
Furthermore, we did in silico drug testing of several model
enzymes. Inhibition of PTGS1 and ALOX5AP caused down-
regulation of PGH2 and PGD2 or 5-HPETE and LTA4,
respectively. These enzymes are known targets to treat inflamma-
tion. PTGS1 (COX-1), for instance, can be inhibited by
Table 2. Kinetic equations and their parameters of the arachidonic acid/eicosanoid metabolism model.




   Vmax=20.56 nM2s21, Km= 2500 nM [BRENDA], Ki= 100 nM,
A1= {PLA2}, A2= {PERK}, I= [AA] nM, S= [PC] nM




   Vmax=0.01 nM2s21, Km= 0.0107 nM, Ki= 8.603 nM, A1= {ALOX5},
A2= {ALOX5AP}, I= [5-HPETE] nM, S= [AA] nM
R3: 5-HPETE R Kcat|S S= [5-HPETE], Kcat= 0.0012s
21




   Vmax=9.7953 nM2s21, Km=99.913 nM, Ki= 0.709 nM, A1= {ALOX5},
A2= {ALOX5AP}, I= [LTA4] nM, S= [5-HPETE] nM
R5: LTA4 R Kcat|S S= [LTA4] nM, Kcat=0.0012 s
21




   Vmax=0.003 nM3s21, Km= 0.067 nM, Ki= 1.004 nM, A1= {ALOX15},
I= [15-HPETE] nM, A2= {PKCD}, A3= {PSTAT3}, S= [AA] nM




   Vmax=1.098 nMs21, Km= 1.58 nM, Ki= 0.0106 nM, A1=ALOX15,
I= [15-HETE] nM, S= [15-HPETE] nM
R8:15-HETE R Kcat|S S= [15-HETE], Kcat= 0.00127 s
21




   Vmax=0.168 nMs21, Km= 3.876 nM, Ki= 0.013 nM,
A= {PTGS1}I= [PGH2], S= [AA] nM
R10: PGH2 R PGD2 Vmax|S|A Vmax=0.067 nMs
21, A= {PTGDS}, S= [PGH2]
R11:PGD2 R Kcat|S S= [PGD2] nM, Kcat=0.052 s
21
R12: AA R Kcat|S S= [AA] nM, Kcat= 0.00096 s
21
A, A1, A2 and A3 are the ratios of gene expression or protein levels of the respective enzymes between DDC-treated vs. control mice. S is the substrate of the corres-
ponding reaction. Squared brackets refer to concentration values and curly braces indicate fold changes of DDC treatment vs. control. The Km value of PLA2 is taken
from BRENDA [55], and other parameters of the table were fitted using the AJ mice metabolic concentrations (see results section).
doi:10.1371/journal.pone.0111006.t002
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mofezolac, SC-560, and other drugs [46]. Inhibition of
ALOX5AP also known as 5-lipoxygenase activating protein, or
FLAP may be useful in the prevention of hepatotoxin-induced
necro-inflammatory injury [47]. Drug molecules can interact with
multiple targets to alter the state and function of the associated
biological network. Licofelone is a novel 5-LOX/COX-inhibitor
which inhibits two enzymes to avoid side effects [48]. Overall, the
dynamics of the AA model can be used for in silico drug studies to
test multiple drugs and potential drug targets. The model
confirmed the upregulation of PGD2 due to DDC treatment
found experimentally. This could be linked to the key transcription
factors/ligand-activated nuclear receptors such as PPARd which
has been implicated as a key regulator of energy homeostasis and
may represent future research avenues to study the interaction of
metabolic and signaling pathways [49].
Prostaglandin E2 (PGE2) was found to be upregulated in AJ and
B6 mice but not in PWD (Fig. 1f). PGE2 promotes inflammation
after binding to prostaglandin E receptor 2 (EP2) [50] and an
inflammatory marker tumor necrosis factor alpha (TNFa)
regulates NASH development in a diet-induced mouse model
[51]. To explain inflammation phenotypes through signaling by
PGE2-EP2-TNFa we observed an upregulation of Tnf expression
(35-fold) in AJ and B6 mice. Upregulation of PGE2 and TNFa in
AJ and B6 mice may explain inflammation of the NASH
phenotype.
The spectrum of NAFLD can be characterized by specific
alterations in hepatic lipid composition. A comprehensive analysis
of plasma lipids and eicosanoids in human revealed a stepwise
increase in lipoxygenease metabolites 5-HETE, 8-HETE and
15-HETE in NAFLD [52]. This correlates with our observations
in the experimental and simulated data, where concentrations of
5-HETE and 15-HETE were increased in DDC mice. Another
study reported overexpression of cyclooxygenase-2 (COX-2) in
hepatocellular carcinoma (HCC) patients [53]. Using immunohis-
tochemistry they studied COX-2 overexpression in different
chronic liver diseases including NASH, chronic hepatitis, and
liver cirrhosis. In our study, we detected overexpression of PTGS1
(COX-2) in DDC mice, which is a key regulator of prostaglandin
formation.
Martı´nez-Clemente et al. demonstrated that hyperlipidemia-
prone apolipoprotein E-deficient (ApoE(2/2)) mice exhibit
hepatic steatosis and increased susceptibility to hepatic inflamma-
tion and advanced fibrosis [54]. They found in an experimental
model the proinflammatory 5-lipoxygenase (5-LO) pathway to be
up-regulated and thus causing liver inflammation and fibrogenesis.
They also found that the inhibition of the 5-LO pathway results in
a significant reduction in liver inflammation. Our data supports an
up-regulation of ALOX5AP through 5-LO pathway due to DDC
treatment in AJ, B6, and PWD, leading to an upregulation of the
downstream component 5-HPETE in the model that is supported
by our experimental data.
In conclusion, mRNA expression data combined with mathe-
matical modeling of metabolic systems provides a useful tool to
better understand cellular metabolism although the correlation
between transcripts and proteins can deviate depending on cellular
location, biological function, and organism [13]. The development
of NAFLD is characterized by broad changes on the molecular
level. Detailed analysis of three differently susceptible mouse
strains, which reflect genetic diversity in humans, showed major
deregulation of arachidonic acid metabolism. Detailed modeling of
Figure 3. Comparison of simulated steady state and experimental metabolite concentrations. Quantitative data of simulated and
experimental metabolite concentrations of all three mouse strains AJ, B6, and PWD for a) control b) DDC treatment, and c) their respective ratios of
the metabolites prostaglandin D2, PGD2; 5- and 15-hydroperoxyeicosatetraenoic acid, 5- and 15-HPETE; 15-hydroxyeicosatetraenoic acid, 15-HETE;
and arachidonic acid, AA.
doi:10.1371/journal.pone.0111006.g003
Figure 4. Identification of key regulatory enzymes (a) and drug testing (b) of the arachidonic acid/eicosanoid metabolism model. a)
Key enzymes or enzyme combinations of the DDC model condition of AJ were reverted to control conditions of this strain to judge the effect on the
change of the metabolite state. Black dots indicate enzymes or enzyme combinations that were reverted to control conditions. Red dots indicate
those enzyme combination that are able to bring back the DDC-treated state to control conditions. b) In silico drug testing of the model by
simulating down-regulation of individual enzyme concentrations as given by their respective expression value by 1/3rd-, 1/6th- and 1/9th of the DDC-
treated state of AJ.
doi:10.1371/journal.pone.0111006.g004
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the arachidonic acid metabolism and model predictions of
metabolic levels are in good agreement with experimental profiles
when the model is initialized by the measured gene and protein
expression data. The study identified deregulated genes, proteins,
metabolites and affected pathways of NAFLD etiology in mouse
and serves as an integrated resource of omics data for the
development of computational models of the disease, such as AA
and SAMe metabolism.
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